(MedPage Today) – Berlin – Belzotevan (Welrig) induced durable responses in advanced pheochromocytoma or paraganglioma (PPGL) in a single-arm phase II trial, evidence supporting recent FDA approval for these very rare neuroendocrine tumors.
New drug for rare neuroendocrine tumors shows lasting activity